US approvals of high-risk medical devices are way down.
Big pharma delivered 76 novel medicines to the market over the past five years, but some companies contributed more than others.
Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
The pricing of Aduhelm has been compared to that of Sovaldi, but this ignores the fact that Sovaldi actually worked.
A green light from the US regulator for aducanumab is a huge boost for Biogen, but not everyone will be celebrating.